Omega-3 (DHA/EPA) for Parkinson's Disease
Also known as: DHA, EPA, Fish oil, Docosahexaenoic acid, Eicosapentaenoic acid
DHA's anti-inflammatory and neurotrophic effects may protect dopaminergic neurons from α-synuclein-driven neuroinflammation.
Mechanism of Action
DHA generates NPD1 and resolvins that resolve neuroinflammation in the substantia nigra. It modulates microglial activation toward anti-inflammatory phenotype, enhances BDNF expression, and reduces α-synuclein aggregation through membrane stabilization.
General mechanism: Essential fatty acids. Neuronal membrane component, SPM precursor, NF-κB inhibitor, anti-cachexia, BDNF enhancer.
Current Evidence
Preclinical models show dopaminergic neuroprotection with DHA supplementation. Epidemiological data suggests dietary omega-3 may reduce PD risk. Clinical trials limited.
Clinical Status: Preclinical positive. Epidemiological support. No PD-specific clinical trials.
Safety Profile
Very safe. Fishy aftertaste. Mild GI effects. Bleeding risk at very high doses. Monitor with anticoagulants.
Key Research Questions
- Can omega-3-derived SPMs resolve PD neuroinflammation?
- Does DHA supplementation slow PD progression as adjunctive therapy?